Skip to content

Anti-aging & longevity

Pinealon

Brain peptide · Pineal peptide

PreclinicalReviewed 18 Aug 2026

Pinealon is one of the short peptide bioregulators developed at the St Petersburg Institute of Bioregulation and Gerontology, each of which is assigned to a specific tissue. It is the one assigned to brain tissue, and it is by some distance the most bought of the family outside Russia. Cognitive claims travel further than claims about the prostate.

It is also the one most often confused with Epitalon, which comes from the same programme and is likewise associated with the pineal gland. They are different compounds with different assignments, and vendor listings blur them freely. If you are buying on something you read about Epitalon, check which one is in the vial.

Everything else about Pinealon is inherited. It rests on one institute's work, spanning decades and never replicated by anyone outside it, and on a proposed mechanism no other compound on this site shares: a peptide two to four amino acids long, said to reach the nucleus and switch on the genes of one tissue. Cognition is also the endpoint where an unblinded self-report is worth least, and almost all of the enthusiasm here is unblinded self-report. That argument and the structural objection to it are set out under Khavinson bioregulator in the glossary, once, because they apply identically to all of them.

How it works

Pinealon is proposed to enter the cell nucleus and bind DNA directly, promoting expression of genes associated with the brain and central nervous system. For the brain the claim is expression of genes associated with neuronal function and resistance to oxidative stress, in the one tissue where a placebo response is hardest to distinguish from anything else.

No independent group has demonstrated any of that. Because the mechanism is described as genomic rather than receptor-mediated, none of the pharmacokinetic reasoning used elsewhere on this site applies: there is no receptor occupancy to model, and no dose-response curve established outside the originating work.

Regulatory status — United States

Not approved for human use in the United States, the European Union or the United Kingdom. Some peptides in this family are registered in Russia as supplements or medicines. Pinealon is sold elsewhere as a research chemical.

Last reviewed 18 Aug 2026. Regulatory positions in this category change frequently; we date this line so you can see how current it is.

What it is studied for

Each entry states the evidence behind it. We do not rank indications by effectiveness — for most compounds here, that would be a claim nobody can support.

Support for the brain and central nervous system

Published review

The claim Pinealon is sold on, and the only one the originating literature makes for it.

EvidenceReported in Russian clinical and animal work from a single institute. Not registered — not blinded to contemporary standards — and never independently replicated.

Identity and clearance

Molecule

Class
Short synthetic peptide bioregulator

Sequences circulate for this family, and we have not stated one here because we could not verify it independently. Publishing an unverified sequence on a page about a compound people inject is not a small error.

Dose protocols reported in sources

Displayed for reference only. Every row says where it came from, and a trial protocol and a community convention are not the same kind of information. None of this is fed into the calculator, and none of it is a recommendation.

Dose protocols reported in sources, with the source of each.
GoalDoseFrequencyRouteUnits, 10 mg vialSourceStart this protocol
Course described in community sources1 mg – 2 mgDaily for a 10-day course, repeated a few times a yearSubcutaneousThe 10-day course is the pattern described across this whole family. It is convention, not a finding. No dose-ranging study establishes it, and the same figures appear for peptides assigned to entirely different organs.10–20 uCommunity practiceStart this

Start this copies a row into a protocol of your own, which you can then edit. Where a source gave a dose range or an ambiguous frequency, those fields arrive empty — we will not pick a number on your behalf.

CheckRows marked community practice describe what people commonly do, drawn from public discussion. They are not derived from any trial and are not evidence that a dose is safe or effective.

Cycling

Community practice

10 days on, Months between courses off.

Described consistently across the family, and consistently without a study behind it.

Calculator

Work out what to draw

Pre-filled with a 20 mg vial as a worked example. These are not recommended values — change them to match the vial in front of you.

Dose unit
Your syringe
010203040506070809010020 units0.2 mL

Draw to 20 units on a 1 mL U-100 syringe. That is 0.2 mL, containing 2 mg of Pinealon.

Concentration10mg / mL
Volume drawn0.2mL
Doses per vial10doses
Per unit100mcg / unit

20 units sits exactly on a printed line.

Bioalmanac performs arithmetic on values you enter. It does not recommend doses, schedules or compounds, and nothing here is medical advice. Confirm every calculation against your vial and syringe before drawing, and speak with a licensed healthcare provider.

Open this calculation in the full calculator

Units, concentration, bacteriostatic water — the glossary defines the vocabulary, and a unit is not a fixed volume.

Safety

Reported effects

  • Generally described as well toleratedPublished review

    Reported in the Russian literature

    That literature is not designed to detect adverse events reliably, so an absence of reports is weak evidence of safety rather than good evidence of it.

  • Injection site irritationCommunity practice

    Occasionally reported

  • Everything elseCommunity practice

    Unknown

    No adverse event has been systematically recorded outside the originating programme.

When to stop

  • Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
  • An injection site that becomes hot, spreading or produces pus.
  • Any new or unexplained symptom you would ordinarily see a doctor about.

Interactions and situations that need care

  • Active or previous cancerAvoid

    The proposed mechanism is switching on gene expression in a target tissue. Whatever one makes of that claim, deliberately pursuing it in someone with malignancy has no supporting evidence and an obvious direction of concern.

  • Pregnancy and breastfeedingAvoid

    No reproductive or developmental safety data, for a compound whose claimed mechanism is gene expression.

  • Any neurological or psychiatric conditionUse caution

    A compound claimed to alter gene expression in brain tissue, with no independent evidence of what it does, is not something to add to a brain already behaving unpredictably.

  • Expecting the Russian literature to mean what a trial meansUse caution

    It is real research, produced over decades, and it is not evaluable the way a registered randomised trial is. Four decades without independent replication is information in its own right, and it points one way.

What to expect

HonestlyThere is no human efficacy data for this compound, so there is no evidence-based timeline to give. Any site publishing a week-by-week schedule of expected effects has invented it.

  • No independent group has replicated the central findings of this family in forty years.
  • The proposed mechanism, short peptides acting directly on chromatin, is not how anything else on this site is understood to work.
  • Peptides in this family differing by one amino acid are assigned to different organs. If that seems like a lot of specificity for one residue, that is the right reaction.
  • The 10-day course pattern is identical across compounds assigned to entirely different tissues, which is a convention, not a dosing finding.
  • Nothing here establishes an effect in people, and the absence of reported harm is not the same as evidence of safety.

Storage and handling

Freeze-dried powder
Refrigerated at 2–8 °C, protected from light.
After mixing
Refrigerated at 2–8 °C. Do not freeze once mixed.
Long-term, frozen
Unopened powder is stable at −20 °C or colder.

Printable one-pagerHow to reconstitute a vial, step by step

Checking your vial

Research chemicals carry no manufacturing standard, so what the vial looks like is often the only quality signal available before you use it. More on assessing quality and COAs.

  • White cake, clear solution

    Standard for a very short peptide.

  • Collapsed cake or cloudy solution

    Heat damage or degradation. Do not use it.

Questions

Is there any Western research on this?
Very little, and none that reproduces the central claims. The body of work is almost entirely from one Russian institute, and it has stood unreplicated elsewhere for decades.
Is Pinealon the same as Epitalon?
No. Both come from the same institute and both are tied to the pineal gland in that literature, which is why they get muddled, but they are separate compounds with separate assignments. Listings and forum posts use the names loosely and vendors are not reliable on the distinction.
Does the oral form work?
Both oral and injected forms are sold with the same claims. For most peptides the route changes everything, because digestion destroys them. That the same effect is claimed either way is a reason for scepticism rather than reassurance.

References

  1. Short peptide bioregulators: the Khavinson programme and its evidential limits

    Russian gerontology and bioregulation literature, 2014 · Body of largely unregistered clinical and animal work from a single institute

    Humans and animals

    Reports tissue-specific effects across a family of di-, tri- and tetrapeptides, attributed to direct interaction with chromatin. Trial registration, pre-specified protocols, blinding to contemporary standards and independent replication are largely absent, and no group outside the originating institute has reproduced the central findings.

  2. Commonly reported community protocols

    Bioalmanac editorial summary of public community sources, 2026 · Not a study

    Records the 10-day course pattern described across this family in public discussion. Carries no evidential weight about safety or effect.

Keep this page honest

If something here is wrong, out of date, or missing a source, tell us and we will fix it and say that we did.

Suggest a correction

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice. No clinician reviews these pages.

Page last updated 18 Aug 2026